Viridian Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on the stock and has a $46.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rami Katkhuda has given his Buy rating due to a combination of factors related to Viridian’s clinical progress and commercial positioning in thyroid eye disease. Although elegrobart’s Phase III efficacy did not fully match leading therapies, both dosing regimens achieved statistically robust and clinically meaningful improvements over placebo on key regulatory endpoints, with benefits seen as early as Week 4.
Rami Katkhuda’s rating is based on the view that elegrobart’s low-volume, self-administered autoinjector format and Viridian’s broader IGF-1R portfolio can capture a substantial share of a roughly $2B and growing “new start” TED market. Physician feedback also supports adoption even with somewhat lower efficacy than current standard of care, and the upcoming REVEAL-2 data plus a planned 2027 BLA filing provide additional value inflection points that underpin the Buy recommendation.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 32.0% and a 53.85% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Disc Medicine.